Prognostic factors in the non-Hodgkin's lymphomas--a time for consensus?
作者信息
Child J A
出版信息
Br J Cancer. 1991 Jun;63(6):837-40. doi: 10.1038/bjc.1991.186.
Abstract
摘要
相似文献
1
Prognostic factors in the non-Hodgkin's lymphomas--a time for consensus?非霍奇金淋巴瘤的预后因素——是达成共识的时候了吗？
Br J Cancer. 1991 Jun;63(6):837-40. doi: 10.1038/bjc.1991.186.
2
Controversies in the management of gastrointestinal non-Hodgkin's lymphomas.
Eur J Surg Oncol. 1989 Dec;15(6):547-52.
3
[The treatment of non-Hodgkin's lymphomas].
Med Clin (Barc). 1990 Dec 1;95(19):743-52.
4
Non-Hodgkin's lymphomas.非霍奇金淋巴瘤
J Natl Compr Canc Netw. 2011 May;9(5):484-560. doi: 10.6004/jnccn.2011.0046.
5
[Strategies in the treatment of non-Hodgkin's lymphomas].[非霍奇金淋巴瘤的治疗策略]
Internist (Berl). 1986 Aug;27(8):485-97.
6
[Non-Hodgkin's lymphoma: morphologic, immunologic and cytogenetic classification].[非霍奇金淋巴瘤：形态学、免疫学及细胞遗传学分类]
Srp Arh Celok Lek. 1996 Sep-Oct;124(9-10):276-82.
7
Chemotherapy of non-Hodgkin's aggressive lymphomas.非霍奇金侵袭性淋巴瘤的化疗
Semin Hematol. 1994 Jan;31(1):46-69.
8
[Diagnostics and staging of non-Hodgkin's lymphomas].[非霍奇金淋巴瘤的诊断与分期]
Internist (Berl). 2007 Apr;48(4):362-71. doi: 10.1007/s00108-007-1824-y.
9
Update: lymphoid neoplasms--molecular characterizations of non-Hodgkin's lymphomas: impact on patient management.更新：淋巴系统肿瘤——非霍奇金淋巴瘤的分子特征：对患者管理的影响
Semin Hematol. 1995 Jul;32(3):237-41.
10
[Staging of non-Hodgkin's lymphoma--recommendations of the Czech Lymphoma Study Group].[非霍奇金淋巴瘤的分期——捷克淋巴瘤研究组的建议]
Klin Onkol. 2010;23(3):146-54.
引用本文的文献
1
Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.土耳其的非霍奇金淋巴瘤：于哈杰泰佩大学的十八年经验
Jpn J Cancer Res. 1994 Dec;85(12):1200-7. doi: 10.1111/j.1349-7006.1994.tb02930.x.
本文引用的文献
1
2
3H-thymidine uptake in chronic lymphocytic leukaemia cells.
Scand J Haematol. 1980 Feb;24(2):169-73. doi: 10.1111/j.1600-0609.1980.tb02363.x.
3
Flow cytometry in the diagnosis and classification of malignant lymphoma and leukemia.流式细胞术在恶性淋巴瘤和白血病的诊断与分类中的应用
Cancer. 1982 Sep 15;50(6):1122-35. doi: 10.1002/1097-0142(19820915)50:6<1122::aid-cncr2820500616>3.0.co;2-q.
4
Prognostic significance of serum lactate dehydrogenase in malignant lymphoma.
Cancer. 1980 Jul 1;46(1):139-43. doi: 10.1002/1097-0142(19800701)46:1<139::aid-cncr2820460122>3.0.co;2-8.
5
Labeling index as a prognostic marker in non-Hodgkin's lymphomas.标记指数作为非霍奇金淋巴瘤的预后标志物
J Natl Cancer Inst. 1981 Jan;66(1):1-5.
6
Serum beta 2-microglobulin in lymphoproliferative and myeloproliferative diseases.
Hematol Oncol. 1984 Oct-Dec;2(4):391-401. doi: 10.1002/hon.2900020409.
7
Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67.采用单克隆抗体Ki-67原位测定恶性非霍奇金淋巴瘤（NHL）的生长分数。
Hematol Oncol. 1984 Oct-Dec;2(4):365-71. doi: 10.1002/hon.2900020406.
8
Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group.非霍奇金淋巴瘤基尔分类的临床及预后相关性：基尔淋巴瘤研究组前瞻性多中心研究结果
Hematol Oncol. 1984 Jul-Sep;2(3):269-306. doi: 10.1002/hon.2900020306.
9
Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma.非霍奇金淋巴瘤患者的血清β2-微球蛋白
Eur J Cancer Clin Oncol. 1983 Mar;19(3):327-31. doi: 10.1016/0277-5379(83)90129-3.
10
Serum beta 2-microglobulin in malignant lymphoma.恶性淋巴瘤中的血清β2-微球蛋白
Cancer. 1983 Jun 15;51(12):2220-5. doi: 10.1002/1097-0142(19830615)51:12<2220::aid-cncr2820511212>3.0.co;2-a.
Zotero 插件